Claims for Patent: 9,371,512

Summary for Patent: 9,371,512

Title:	Method for the production of permanent human cell lines
Abstract:	The present invention relates to a permanent human cell line comprising a nucleic acid sequence for the adenoviral gene functions E1A and E1B and the nucleic acid sequence for the SV40 large T-antigen or the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1). Further, the present invention relates to a method for transient expression of recombinant polypeptides and proteins in said permanent human cell line.
Inventor(s):	Schiedner; Gudrun (Cologne, DE), Volpers; Christoph (Wiesbaden, DE)
Assignee:	CEVEC PHARMACEUTICALS GMBH (Cologne, DE)
Application Number:	13/147,775
Patent Claims:	1. A method for the production of a permanent human amniocytic cell line comprising: a) transfecting primary human amniocytic cells with a nucleic acid molecule comprising a nucleic acid sequence encoding the human adenoviral serotype 5 gene products E1A and E1B to produce clonal transformed human amniocytic cells; b) isolating and expanding the clonal cells to produce a single transformed human amniocytic cell clone; c) expanding the single transformed human amniocytic cell clone of step (b) to produce a uniform transformed human amniocytic cell line having stable, high growth density and transient protein expression, and d) stably transfecting the transformed human amniocytic cells of step (c) with a nucleic acid molecule comprising a nucleic acid sequence encoding the SV40 large T-antigen operably linked to a CMV promoter or CAG promoter to produce a permanent human amniocytic cell line expressing SV40 large T-antigen, wherein said permanent human amniocytic cell line exhibits about a 25 to 70 fold increase in transient expression of recombinant protein compared to amniocytic cells not expressing SV40 large T-antigen when subsequently transfected with a nucleic acid encoding the recombinant protein. 2. The method of claim 1, wherein the human adenovirus serotype 5 sequence comprises the nucleotides 1 to 4344, 505 to 3522 or the nucleotides 505 to 4079 of the human adenovirus serotype 5. 3. The method of claim 1, wherein the nucleic acid sequence encoding the SV40 large T-antigen further comprises a nucleic acid sequence for SV40 SD/SA (intron) and the nucleic acid sequence for SV40 polyA. 4. A method for transient expression of a recombinant polypeptide from the permanent human amniocytic cell line of claim 1 comprising: a) transfecting the permanent human amniocytic cell line expressing SV40 large T-antigen with a nucleic acid molecule comprising a nucleic acid sequence encoding a recombinant polypeptide and a recognition or binding site for SV40 large T-antigen therein, b) culturing the permanent human amniocytic cell line under conditions allowing the expression of said recombinant polypeptide, and subsequently c) isolating said recombinant polypeptide from the cells or from the culture supernatant. 5. The method of claim 4, wherein the recombinant polypeptide is a hormone, a plasma factor, a blood clotting factor, a growth factor, a cellular receptor, a fusion protein, a Coxsackie and adenovirus receptor (CAR), an antibody, a viral, bacterial or parasitic antigen or complement factor for the production of recombinant viruses. 6. The method of claim 1, wherein said permanent human amniocytic cell line exhibits about a 30-fold increase in transient expression of recombinant protein compared to amniocytic cells not expressing SV40 large T-antigen. 7. The method of claim 1, wherein said permanent human amniocytic cell line exhibits about a 40-fold increase in transient expression of recombinant protein compared to amniocytic cells not expressing SV40 large T-antigen. 8. The method of claim 1, wherein said permanent human amniocytic cell line exhibits about a 70-fold increase in transient expression of recombinant protein compared to amniocytic cells not expressing SV40 large T-antigen.

Details for Patent 9,371,512

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-02-05
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-02-05
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-02-05